269 results
Page 5 of 14
8-K
EX-99.1
7n8j2n5p04dyh im
27 Jan 14
BioTime, Inc. Subsidiary OncoCyte Corporation Initiates Clinical Development of Bladder Cancer Diagnostics in the United States and China
12:00am
8-K
EX-99.1
cu4r0yz62ube rh3sn1
17 Jan 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
n9zizih7gj1bdz4jz2h3
13 Jan 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
l59rcml
2 Jan 14
Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Leases Facilities for Expanded Product Development and Manufacturing
12:00am
8-K
EX-99.1
pp0im5ju utsy1
23 Dec 13
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.7 Million Grant From Israel’s Office of the Chief Scientist
12:00am
8-K
EX-99.1
astu pk13a19
6 Dec 13
LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards® Version 3.11
12:00am
8-K
EX-99.1
0so5 zowhth2o
4 Dec 13
BioTime’s CEO, Dr. Michael West to Moderate Session on Mapping the Cellular Basis of Life at the 2013 World Stem Cell Summit
12:00am
8-K
EX-99.1
ts1rkw
2 Dec 13
Asterias Biotherapeutics, Inc. Files Registration Statement for Underwritten Public Offering
12:00am
8-K
EX-99.1
d9p3mwwz
25 Nov 13
BioTime CEO Dr. Michael West to Present at 11th Annual Commercial Translation of Regenerative Medicine Conference
12:00am
8-K
j7y3w
28 Oct 13
BioTime Organizes New ESI BIO Division to Develop, Manufacture and Market the Company’s Cell-Based Research Products
12:00am
8-K
EX-99.1
wcznpzq a63q9
28 Oct 13
BioTime Organizes New ESI BIO Division to Develop, Manufacture and Market the Company’s Cell-Based Research Products
12:00am
8-K
EX-99.1
u25ciru
28 Oct 13
BioTime Reports Interim Results on Renevia™ Clinical Safety Trial
12:00am
8-K
EX-99.1
z0eautfd2oh0ydyh9l
28 Oct 13
Regulation FD Disclosure
12:00am
8-K
EX-99.1
motoa4r
4 Oct 13
BioTime Announces Additional Products in Development Based on HyStem® Technology
12:00am
8-K
ez4 oygyppu
4 Oct 13
BioTime Announces Additional Products in Development Based on HyStem® Technology
12:00am
8-K
EX-99.1
ozgzvr w2ciy2
1 Oct 13
Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Acquires Geron’s Embryonic Stem Cell Assets
12:00am
8-K
EX-99.1
d1v4yy57w08tzn eje3
19 Sep 13
BioTime Signs Exclusive Agreement with Jade Therapeutics for Ophthalmic Drug Delivery Applications of HyStem® Technology
12:00am
8-K
EX-99.1
e3d8tm3
28 Aug 13
BioTime Receives Approval to Begin Human Clinical Trials of Renevia
12:00am